Markets:

Overview

News

Currencies

International

Treasuries

89bio, Inc. - Common Stock (NQ:ETNB)

14.84 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know ↗

July 03, 2023

Via Benzinga

Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 03, 2023

Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to...

Via Benzinga

What 6 Analyst Ratings Have To Say About 89bio ↗

July 03, 2023

Via Benzinga

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

June 24, 2023

From 89bio, Inc.

Via GlobeNewswire

Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

June 24, 2023

From 89bio, Inc.

Via GlobeNewswire

Analyst Ratings for 89bio ↗

May 08, 2023

Via Benzinga

3 Biotech Buyout Targets to Watch ↗

April 29, 2023

The trio all have late-stage therapies with blockbuster potential.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023 ↗

June 13, 2023

Via Benzinga

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

June 07, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19

April 19, 2023

Via Investor Brand Network

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

May 23, 2023

First FGF21 analog to enter Phase 3 development

From 89bio, Inc.

Via GlobeNewswire

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 04, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

May 02, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10

April 10, 2023

Via Investor Brand Network

89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31

March 31, 2023

Via Investor Brand Network

Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying ↗

March 31, 2023

Although US stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

89Bio Inc. (NASDAQ: ETNB) Records 52-Week High Friday Morning

March 24, 2023

Via Investor Brand Network

Why Shares of 89bio Soared This Week ↗

March 24, 2023

The company released positive results for its lead therapy.

Via The Motley Fool

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

March 24, 2023

From 89bio, Inc.

Via GlobeNewswire

KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday ↗

March 23, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

89Bio Inc. (NASDAQ: ETNB) Near the Top of Equities by Percentage Gain on 3/22

March 22, 2023

Via Investor Brand Network

Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 23, 2023

Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.

Via Benzinga

89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday ↗

March 23, 2023

Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose...

Via Benzinga

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

March 22, 2023

From 89bio, Inc.

Via GlobeNewswire

Dow Rises 75 Points; Fed Increases Rates By 25bps ↗

March 22, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 75 points on Wednesday. The Dow traded up 0.23% to 32,635.71 while the NASDAQ rose 0.65% to 11,932.62. The S&P...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 22, 2023

Via Benzinga

Why 89bio Shares Are Trading Higher Today ↗

March 22, 2023

89bio (NASDAQ: ETNB) shares are trading higher on Wednesday after the company's Phase 2b ENLIVEN trial of pegozafermin in NASH achieved statistical significance on both primary histology endpoints.

Via Benzinga

Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 22, 2023

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

Via Benzinga

Nasdaq Edges Higher; Crude Oil Rises 1% ↗

March 22, 2023

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving higher on Wednesday. The Dow traded down 0.15% to 32,512.83 while the NASDAQ rose 0.13% to 11,875.36. The S&P 500, also...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.